Additional file 1 of Immunogenicity, efficacy, and safety of SARS-CoV-2 vaccine dose fractionation: a systematic review and meta-analysis
Creators: name: Yang, Bingyi
name: Huang, Xiaotong
name: Gao, Huizhi
name: Leung, Nancy H.
name: Tsang, Tim K.
name: Cowling, Benjamin J.
Publisher: name: figshare
Year: 2022
Subjects: subject: Immunology
subject: FOS: Clinical medicine

description: Additional file 1: Table S1. Search strategy and number of articles identified in each step. Table S2. Summary of 38 studies that were included for systematic review analysis. Table S3. Summary of 38 studies that were included for analyses of seroconversion and dose-response relationship of neutralizing antibodies. Table S4. Summary of 17 studies that are included for cell-mediated response analysis by vaccine type. Table S5. Factors associated with neutralizing antibody responses after receiving different fractional doses of vaccinations. Table S6. Cross-validation of general additive model for dose-response relationship of neutralizing antibody after fractional doses. Table S7. Fold of reduction in neutralizing antibodies against variants of concerns. Table S8. Vaccine effectiveness against infections of variants of concern for standard dose. Table S9. Factors associated with risk of experiencing seroconversion of neutralizing antibodies after receiving non-standard and standard doses. Fig. S1. Flowchart of literature search and screening. Fig. S2. Risk of bias of 39 included studies. Fig. S3. Model predictions of dose-response relationship of neutralizing antibodies (nAbs) against ancestral strains introduced by COVID-19 vaccines. Fig. S4. Standardized neutralizing antibodies (nAbs) introduced by COVID-19 vaccines on day 0 since the complete vaccination. Fig. S5. Standardized neutralizing antibodies (nAbs) introduced by COVID-19 vaccines on day 14 since the complete vaccination. Fig. S6. Standardized neutralizing antibodies (nAbs) introduced by COVID-19 vaccines on day 28 or later since the complete vaccination. Fig. S7. Associations between time since complete vaccination and the standardized neutralizing antibodies (nAbs) against the ancestral strains elicited by fractioning dose of COVID-19 vaccines. Fig. S8. Dose-relationship between dose fractionation and predicted vaccine efficacy against symptomatic infections of variants of concern. Fig. S9. Correlation between predicted and observed vaccine efficacy against variants of concern for standard dose of COVID-19 vaccines. Fig. S10. Comparison of T-cell responses against the ancestral strains elicited by higher doses of COVID-19 vaccines. Fig. S11. Comparison of safety after vaccinated with lower doses (a) and higher doses (b) to standard doses of SARS-CoV-2 vaccines. Fig. S12. Pooled risk ratio (in log scale) of experiencing solicited local adverse events after vaccinated with fractional and standard dose groups. Fig. S13. Pooled risk ratio (in log scale) of experiencing solicited systemic adverse events after vaccinated with fractional and standard dose groups. Fig. S14. Pooled risk ratio (in log scale) of experiencing any solicited adverse events after vaccinated with fractional and standard dose groups. Fig. S15. Pooled risk ratio (in log scale) of experiencing any unsolicited adverse events after vaccinated with fractional and standard dose groups. Fig. S16. Pooled risk ratio (in log scale) of experiencing any adverse events after vaccinated with fractional and standard dose groups.